Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trialEugenio Mercuri, Katie Groves, Francesco Muntoni et al.|The Lancet Neurology|2021Cited by 260
Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 TrialLaurent Servais, Frederick J. Schnell, Baoguang Han et al.|Nucleic Acid Therapeutics|2021Cited by 128
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersenValeria Sansone, Giorgia Coratti, Maria Carmela Pera et al.|European Journal of Neurology|2020Cited by 19
Predominant distal muscle involvement in spinal muscular atrophyClaudia Brogna, Eugenio Mercuri, Lara Cristiano et al.|Neuromuscular Disorders|2019Cited by 4
P.222Long term progression in type II spinal muscular atrophy: a retrospective observational studyEugenio Mercuri, Marika Pane, Simona Lucibello et al.|Neuromuscular Disorders|2019Cited by 0